CMC Pharmaceuticals, a provider of drug product development services to the pharmaceutical and biotechnology industries, has formed an Advisory Board. The group of leaders will advise CMC Pharma on continued growth with a focus on cutting-edge science, business strategy, marketing, and risk reduction. The Members have decades of experience in government, commercial, and academic research and development with demonstrated success including several biotech start-ups.
 
Board Members include Drs. John Patton, Mark Prausnitz, W. Mark Saltzman, Arthur Tipton, and Larry Zeitlin. The team at CMC Pharma, led by owner and co-founder, Dr. Mike Radomsky, helps clients with their drug product development efforts, ranging from early-stage formulation and analytical methods work to commercial-stage support. 
 
“The team at CMC Pharma has many decades of technical drug development experience, fast response times, and current capacity to begin new projects,” said Dr. Radomsky. “The formation of an Advisory Board allows us to network and strategize with academics and industry leaders, navigating new routes for expansion while continuing to use our strengths to our advantage.”
 
Dr. Art Tipton, Chairman, is an independent consultant who aids companies in developing the next generation of drug delivery products. He was part of three successful drug delivery companies, including Founder and CEO of Brookwood Pharmaceuticals, now part of Evonik.  He holds 43 U.S. patents and is an elected member of the National Academy of Inventors, the College of Fellows for the American Institute of Medical and Biological Engineering,  The Controlled Release Society, and the National Academy of Engineers.
 
Dr. John Patton spent the first 16 years of his career in academia as a lipid biochemist and marine biologist. He then left to lead the drug delivery team at Genentech in 1985. Since then, he acquired extensive experience in biotech industry drug delivery startups, where he co-founded Inhale/Nektar Therapeutics, Dance BioPharm, InCarda, and iPharma Limited. He is now the CEO of Tesio Pharmaceuticals and the founding investor of Halozyme. Dr. Patton is a Fellow of the Controlled Release Society.
 
Dr. Mark Prausnitz is a Regent’s Professor and J. Erskine Love, Jr. Chair in Chemical and Biomolecular Engineering at the Georgia Institute of Technology. He received a BS degree from Stanford University and Ph.D from MIT, both in chemical engineering. He has published more than 300 journal articles and has co-founded seven startup companies including Micron Biomedical and Clearside Biomedical.
 
Dr. W. Mark Saltzman is an engineer and educator who has authored three textbooks and has served as a faculty member at Johns Hopkins University, Cornell University, and Yale University. He is the founding chair of Yale’s Department of Biomedical Engineering and the Head of Yale’s Jonathan Edwards College. He has been recognized for excellence in research and teaching and has been the recipient of numerous awards and has been elected a Fellow of the American Institute for Medical and Biological Engineering, the Biomedical Engineering Society, and more.
 
Dr. Larry Zeitlin received his doctorate in Reproductive Biology from Johns Hopkins University and served as a Research Scientist at ReProtect, and a Senior Scientist at Epicyte Pharmaceuticals. He co-founded Mapp Biopharmaceutical and ZabBio, and serves as President for both companies. His career focus has been on the development of monoclonal antibody-based products to address unmet public health needs in infectious disease.